Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.59 |
| ▸ | BCL2 | P10415 | 15/20 | 0.59 |
| ▸ | BCL2L2 | Q92843 | 3/20 | 0.45 |
| ▸ | BAD | Q92934 | 2/20 | 0.43 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503690 | 0.90 | BCL2L1 (0.61) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL431063 | 0.90 | BCL2L1 (0.61) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL431064 | 0.90 | BCL2L1 (0.61) | BCL2L1BCL2BCL2L2MCL1 | |
| SCHEMBL13503714 | 0.84 | BCL2L1 (0.62) | BCL2L1BCL2 | |
| SCHEMBL13503819 | 0.83 | BCL2L1 (0.44) | BCL2L1BCL2MCL1 | |
| SCHEMBL13504111 | 0.82 | BCL2L1 (0.45) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL13681478 | 0.81 | BCL2L1 (0.55) | BCL2L1BCL2 | |
| SCHEMBL13503539 | 0.80 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL376606 | 0.80 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2 | |
| SCHEMBL13503818 | 0.80 | BCL2L1 (0.61) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | BCL2L1 18/4885BCL2 2/4885BCL2L2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.